Cited 0 times in
인터페론 단독 투여에 지속적 치료 효과가 없었던 만성 C 형 간염 환자에서의 인터페론과 리바비린의 병용 치료
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김현숙 | - |
dc.contributor.author | 이관식 | - |
dc.date.accessioned | 2020-01-23T05:11:11Z | - |
dc.date.available | 2020-01-23T05:11:11Z | - |
dc.date.issued | 1999 | - |
dc.identifier.issn | 1598-9992 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/174072 | - |
dc.description.abstract | Background/Aims: Interferon-alpha has been effective in 10-20% of treated patients with chronic hepatitis C (CH-C) on a long term basis. We conducted this study to evaluate the biochemical and virological outcomes of combined treatment with interferon alpha and ribavirin for the patients who had CH-C but showed non-response or relapse to interferon alpha alone. Methods: Twenty five patients with CH-C who had not responded or relapsed to interferon alpha alone treatment were enrolled. Eighteen patients were given by the combined treatment of interferon alpha and ribavirin and 7 patients were not given any specific treatment as control. Interferon alpha-2a was given subcutaneously, at a dose of 4.5 MU thrice weekly. Ribavirin was also given orally, at a dose of 900 mg/day for 24 weeks. We quantified serum HCV-RNA levels at the end of treatment. Results: The normalization rate of serum ALT at the end of treatment was 47.1% (8/17) in treated group and 14.3% (1/7) in control group and negative conversion of HCV-RNA was noted in all patients. In the treated group, 75% (6/8) of responders at the end of treatment sustained serum ALT level normally during 24 weeks follow-up, but none has responded persistently in the control group. Conclusions The combined treatment with interferon alpha and ribavirin is effective and safe for treating chronic hepatitis C in patients who showed non-response or relapse to interferon alone. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | Korean Journal of Gastroenterology | - |
dc.publisher | Korean Journal of Gastroenterology | - |
dc.relation.isPartOf | Korean Journal of Gastroenterology | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | 인터페론 단독 투여에 지속적 치료 효과가 없었던 만성 C 형 간염 환자에서의 인터페론과 리바비린의 병용 치료 | - |
dc.title.alternative | Combined Treatment with Interferon Alpha and Ribavirin for Chronic Hepatitis C in Patients with Previous Non-response or Relapse to Interferon Alone | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Laboratory Medicine (진단검사의학교실) | - |
dc.contributor.googleauthor | 이천균 | - |
dc.contributor.googleauthor | 한광협 | - |
dc.contributor.googleauthor | 정정일 | - |
dc.contributor.googleauthor | 최원 | - |
dc.contributor.googleauthor | 최병현 | - |
dc.contributor.googleauthor | 김부일 | - |
dc.contributor.googleauthor | 이관식 | - |
dc.contributor.googleauthor | 전재윤 | - |
dc.contributor.googleauthor | 문영명 | - |
dc.contributor.googleauthor | 김영아 | - |
dc.contributor.googleauthor | 김현숙 | - |
dc.contributor.localId | A01117 | - |
dc.contributor.localId | A02666 | - |
dc.relation.journalcode | J02015 | - |
dc.identifier.eissn | 2233-6869 | - |
dc.subject.keyword | Chronic C viral hepatitis | - |
dc.subject.keyword | Interferon alpha | - |
dc.subject.keyword | Ribavirin | - |
dc.subject.keyword | Non-response and relapse | - |
dc.contributor.alternativeName | Kim, Hyon Suk | - |
dc.contributor.affiliatedAuthor | 김현숙 | - |
dc.contributor.affiliatedAuthor | 이관식 | - |
dc.citation.volume | 33 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 232 | - |
dc.citation.endPage | 239 | - |
dc.identifier.bibliographicCitation | Korean Journal of Gastroenterology, Vol.33(2) : 232-239, 1999 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.